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Abstract 
Background and Aim. 
Parathyroidectomy is the standard treatment for primary hyperparathyroidism (PHPT). Cinacalcet, an 
allosteric modulator of the calcium sensing receptor, has been shown to be effective in reducing serum 
calcium levels and it  has gained prominence as a non-invasive treatment in PHTH. Aim of the study was 
to compare the efficacy and tolerability of medical therapy vs surgery in a cohort of PHPT patients.  
Patients and Methods. 
The study included 63 consecutive subjects (14 men and 49 women, median age 62.4 ± 12 yr) with PHPT: 
50 subjects (40 F and 10 M, ratio F/M 4:1; median age 59.6 ± 16.6 years, range 37-82) underwent 
parathyroidectomy, while 13 (9 F and 4 M, ratio F/M 2.5:1, median age 76.5 ± 6.2 years, range 64-83), 
who were ineligible for surgery, were treated with cinacalcet. Cinacalcet was administered at increasing 
dosages until normal serum calcium was reached or side effects occurred. Serum calcium and PTH was 
measured and adverse events were monitored during a 12 month-duration follow-up. 
Results. 
All patients who had undergone parathyroidectomy normalized both serum calcium and PTH levels after 
surgery (P=0.001 vs baseline) and none of them experienced persistent and/or recurrent PHPT during 
follow-up. In the group under cinacalcet therapy, serum calcium significantly decreased in all patients 
within 4 weeks (P = 0.01 vs baseline) and normalized in all patients at prolonged follow-up (P=0.001 vs 
baseline), while PTH slightly decreased during follow-up (P=0.878 vs baseline) and never reached a 
normal value. 
Conclusion. 
Surgical treatment is curative and safe in most cases of PHPT.  Cinacalcet represents an effective 
therapeutic option, from the perspective of hypercalcemia improvement, in PHPT patients who have 
contraindications to surgery or persistent PHPT after surgery. 
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Introduction 
Primary hyperparathyroidism (PHPT) is characterised by elevated secretion of parathyroid hormone 
(PTH) leading to hypercalcaemia (1). Its incidence increases with age especially in women, with a 
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prevalence of 21/1000 in women between 55 and 75 years-old, corresponding to 3/1000 in the general 
population, but it is the same in two sex before 45 years (2). PHPT is most often caused by a single 
adenoma (80 to 85%) or four-gland hyperplasia (10 to 15%), mainly occurs as a sporadic disease but it 
may be part of a hereditary syndrome, including multiple endocrine neoplasia (MEN) types 1, 2A, and 
4, hyperparathyroidism-jaw tumor (HPT-JT) syndrome, familial isolated hyperparathyroidism, familial 
hypocalciuric hypercalcemia (FHH), and neonatal severe PHPT (3, 4).Although the disease is often 
asymptomatic, complications can be progressive and/or severe, including bone loss and fractures, 
kidney stones and gastrointestinal disturbances; symptoms such as muscle weakness, depression, and 
neuropsychiatric disturbance have also been reported.  
Parathyroidectomy (PTx) is the therapeutic procedure able to cure the disease and has a success rate of 
up to 90–95% (5). Surgery should be considered in moderate-to-severe PHPT and in presence of 
symptoms of hypercalcemia or complications and should be advised in patients with asymptomatic 
PHPT who meet the criteria for surgery according to the latest international guidelines (6) About 5–12% 
of patients with PHPT may have persistent or recurrent PHPT after parathyroidectomy (7). Repeating 
surgery could be associated with increased incidence of complications, including recurrent laryngeal 
nerve damage or permanent hypoparathyroidism (8). 
Patients with persistent PHPT after parathyroidectomy or with contraindications for surgery or patient 
who refuse undergoing operation have few treatment options currently available. 
Cinacalcet hydrochloride is an allosteric modulator of the calcium sensing receptor (CaSR) which is 
strongly expressed on the surface of parathyroid cells as well as in other tissues (9). Cinacalcet enhances 
the sensitivity of the CaSR to the prevailing extracellular calcium, resulting in an increase in the 
intracellular calcium concentration and a concomitant reduction in PTH released by the parathyroid gland. 
Cinacalcet reduces serum calcium and PTH levels in patients with mild PHPT compared with placebo 
(10) and significantly lowers serum calcium by greater than 1 mg/dl (0.25 mmol/liter) in more than 60% 
of patients with parathyroid cancer (11) and Multiple Endocrine Neoplasia type 1 (MEN 1) (12)  
The present study was aimed at evaluating the effectiveness of cinacalcet in reducing serum calcium 
and PTH concentrations in PHPT patients ineligible for, or unwilling to undergo, surgery  in 
comparison with PHPT patients who undergone PTx. Secondary objectives were to assess the safety of 
cinacalcet compared to surgery. 
Patients and methods 
Patients. 
Sixty-three consecutive patients (14 men and 49 women, median age 62.4 ± 12 yr) diagnosed with 
PHPT at the Endocrine Unit of the University Hospital “AOU Policlinico G. Martino” of Messina were 
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included in the study. Each subject received a careful medical evaluation, including recording of past 
personal and family medical history, and physical examination. PHPT was diagnosed by the currently 
accepted laboratory and instrumental criteria (13). Fifty patients (40 F and 10 M, ratio F/M 4:1; median 
age 59.6 ± 16.6 years, range 37-82) underwent parathyroidectomy (PTx). The remaining 13 patients (9 
F and 4 M, ratio F/M 2.5:1, median age 76.5 ± 6.2 years, range 64-83), who were ineligible for on 
unwilled to undergo surgery, were treated with cinacalcet. The 13 patients were candidate to medical 
treatment because they had a serum calcium concentration >1 mg/dL upper limit of normal. Patients 
initially received cinacalcet 30 mg twice daily. The dosage was increased to the next sequential dosage 
every 2 weeks, depending on the patient’s serum calcium concentration during the previous week and 
an adverse event assessment. Dosage escalation continued until the serum calcium concentration was 10 
mg/dl or less (2.5 mmol/liter). The observational period was 12 months from enrollment. 
Informed consent was obtained, and the study was approved by our local Ethics Committee. 
Methods. 
Peripheral blood samples were collected after overnight fasting from all the recruited patients at baseline 
and at each follow-up visit. In the  subset of patients under medical treatment, samples for serum 
calcium and PTH were collected before the morning dose of cinacalcet. Venous blood was centrifuged 
at 1450xg at 4 °C for 10 min. Urine was collected over 24 h after an overnight fasting at baseline. All 
samples were processed centrally in the laboratory of our University Hospital of Messina. Serum 
calcium (normal values 8.4-10.4 mg/dl) and phosphorus  (normal values 2.5-4.5 mg/dl), as well as 
urinary calcium and phosphorus (normal values 100-300 mg/24h and 300-800 mg/24h, respectively) 
and alkaline phosphatase (normal values 40-150), were measured using commercial kits on routine 
methods. Serum intact PTH was measured using a solid-phase, two-site, chemiluminescent, enzyme-
labeled, immunometric assay (Immulite 2000; normal values 12–62 pg/ml in our laboratory). To 
evaluate the vitamin D status, 25(OH)D3 was measured by HPLC (Bio-Rad Laboratories S.r.l., Milano, 
Italy). For all assays, the intra or the inter-assay CV were <5 and <10%, respectively. 
Statistical analysis 
Data re expressed as mean ± SD, median and range. Statistical analyses were performed by t test, using 
SPSS 17.0 for Window package. P<0.050 two sided was considered to be statistically significant. 
Results 
Demographic, clinical and biochemical features of our study population are summarized in Table 1. 
Patients were divided in two groups: group A included 50 patients who underwent 
parathyroidectomy, group B included 13 patients who were treated with cinacalcet. 
As reported in Table 1, female sex was more represented in both groups (49 females, 14 males, 
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F:M ratio 3.5:1), and the median age at diagnosis was significantly higher in group B compared 
to group A patients (P=0.001). The two groups did not differ with respect to the main 
biochemical parameters at pre-surgical evaluation.  
Table 1. Dermographic, clinical and biochemical features of our study population 
 
 
CINACALCET PARATHYROIDECTOMY P 
No. of patients 13 50 
Sex 
Male 
Female 
 
4 
9 
 
10 
40 
Age 
median ± SD 
 
76.5 ± 6.2 (64-83) 
 
59.6 ± 11.3 (32-80) 
Creatinine(mg/dl) 0.85 ± 0.12 (0.6-1) 0.79 ± 0.18 (0.6-1.3) 
Urea (mg/dl) 39.6± 5.7 (34-48) 37.9± 6.5 (27-48) 
Calcium(mg/dl) 11.7± 0.4 (11.5-12.1) 11.5 ± 1 (11.4-15) 
Phosphorus(mg/dl) 2.9 ± 0.3 (2.4-3.5) 3.0 ± 0.4 (2.5-3.5) 
Urinary calcium(mg/24h) 343.9 ± 102.7 (37.5-476) 303.3± 110.7(55.4-410) 
Urinary Phosphorus(mg/24h) 497 ± 95 (395-600) 470± 89 (390-530) 
25(OH)D3(ng/ml) 29.8± 10.5 (10.4-44) 29.88± 8.7 (13-41) 
PTH (pg/ml) 314.8 ± 306.8 (65.7-869) 242.6 ± 193.4 (65-1060) 
Alkaline phosphatase (UI/L) 76 ± 17.3 (66-96) 116.6 ± 48.6 (55-201) 
Indication for cinacalcet treatment were as follows: a) contraindication to PTx (n=10, 77%); b) 
PTx refusal (n=2; 15%); c) persistent PHPT after parathyroidectomy (n=1; 8%). 
Group A 
All patient who underwent PTx had a significant decrease in serum calcium 24 hours after surgery. 
Transient hypocalcemia occurred in 5 patients, requiring calcium supplementation for 2-4 weeks. In all 
patients serum calcium significantly decreased, reaching normal values at first evaluation 1 month after 
surgery (P=0.001) and at prolonged follow-up (P=0.001) (Table 2 and Fig. 1 A). 
Intra-operative assessment of PTH was performed in 9 patients and showed a decrease of 
PTH by 74.7% compared to baseline in all but one patients (Table 3). In all patients PTH values 
decrease to normal values 24 hours after surgery and so remained during the whole duration 
of follow-up (P = 0.001 compared to baseline) (Table 2 and Fig. 1 A). 
None had persistence or recurrence of PHPT. 
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Table 2. Calcium and PTH values during the follow-up 
 
 
Pre-surgery Post-surgery 
 1° Month 3° Month 6° Month 12° Month 
Group A      
Calcium 
(mg/dl) 
 
11.5 ± 1 (11.4-15) 9.05 ± 0.85** 
(7-10.3) 
9,3  ±  0,9** 
(4,4-10,6) 
9,3 ±  0,5** 
(8,4-9,6) 
9,2 ± 0,5** 
 (8,2-9,7-9) 
PTH  
(pg/ml) 
 
242,6  ±  193,4  
(65-1060) 
68.6  ±  12.2** 
(3.3-75) 
42,7 ± 17,9 ** 
(11,5-69,3) 
57,1 ± 26,3** 
(13,5-72) 
36,3 ±  6 *** 
(23,2-41) 
Group A: 50 patients undergone surgery. Group B: 13 patients under cinacalcet treatment. Data are mean + standard deviation. 
*P=0.01; ** P=0.001; ***P=0.0001  compared to baseline 
 
Pre-treatment Post-treatment 
 1° Month 3° Month 6° Month 12° Month 
Group B      
Calcium 
(mg/dl) 
 
11.7 ± 0.4  (11.5-
12.1) 
10.5 ± 0.9* 
(9.6-12.3) 
9.6 ± 0.7 ** 
(9.0-11.2) 
9.5 ± 0.3 ** 
(9.1-9.9) 
9.9 ± 0.3** 
(9.4-10.2) 
PTH  
(pg/ml) 
 
242,6  ±  193,4  
(65-1060) 
68.6  ±  12.2** 
 (3.3-75) 
42,7 ± 17,9 ** 
(11,5-69,3) 
57,1 ± 26,3** 
(13,5-72) 
36,3 ±  6 *** 
(23,2-41) 
At pathological examination all but one patients were diagnosed with a benign parathyroid 
adenoma. One patient, an80-year-old male, was found to have a parathyroid carcinoma, without 
any pre-operative suspicious of malignancy. Pre-operatively, he had elevated serum PTH (219.04 
pg/ml; nv 12–62)  and total (13.10 mg/dl; nv 8.2–10.4) and  ionized calcemia (1.6 mmol/L; n.v. 
1.1-1.3), as well as hypercalciuria (*410 mg/24hvitamina). Thus, this patient was not 
characterized by very high levels of serum calcium and PTH, as commonly expect in parathyroid 
cancer patients, and the diagnosis was made after surgery.As regards surgical complication, two 
patients experienced a transient dysphonia. 
Group B 
Of the 13 patients treated with cinacalcet, 9 completed the 12-month follow-up period, while 4 
patients discontinued the treatment for adverse effects, 3 within the first month of therapy and 
one after 3 months. The most frequent adverse effects recorded were nausea resistant to therapy 
(50%), xerostomy (25%) and muscle spasms (25%). Nohypocalcemic events were recorded.  
Cinacalcet was started at the dose of 30 mg twice daily and was increase to 60 mg twice daily in 
6 patients within 4 weeks, until normal serum calcium was reached.  
Serum calcium significantly decreased during titration phase of therapy (first month), despite it 
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was significantly higher compared to patients undergone PTx (10.5 ± 0.9 mg / dl vs 9.05 ± 0.85 
mg/dl  P <0.01). Starting from month 2, all patient reached the maintenance cinacalcet dose 
(mean 30 mg twice daily, range 30 daily-60 mg twice daily), that remained  constant during the 
following months. Starting from month 2, all patients achieved normal calcium values (≤10.2 
mg/dl; 2.575 mmol/l). At last control (12 months), serum calcium was significantly reduced 
compared to baseline (P = 0.01) (Table 2 and Fig. 1 B ) and was not different from the calcium 
values recorded in patients who had undergone PTx  (9.9± 0.3 mg/dl vs 9.2±0.9 mg/dl; P> 0.05). 
In all 13 patients PTH slightly decreased during follow-up (Table 2 and Fig. 1 B ) and never 
reached a normal value.  
Table 3. Intra-operative assessment of PTH 
 
 
Pre-operative PTH Intra-operative PTH Reduction(%) 
339 pg/dl 39 pg/dl 88,50 
1060 pg/dl 279 pg/dl 73,68 
263 pg/dl 42 pg/dl 84,0 
218 pg/dl 83 pg/dl 61,93 
131 pg/dl 90 pg/dl 31,30 
131 pg/dl 26 pg/dl 80,15 
120 pg/dl 28 pg/dl 76,67 
3030 pg/dl 650 pg/dl 78,55 
277 pg/dl 20 pg/dl 92,78 
   
 
Figure 1. Changes in serum calcium and intact PTH from baseline over time after 
parathyroidectomy (A) and during cinacalcet treatment (B) 
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Discussion 
In this study on a small cohort of patients suffering from PHPT, all subjects who received 
cinacalcet had their serum calcium lowered into the normal reference range during prolonged 
follow-up (12 months), as well as subjects who had undergone surgery. Serum PTH was lowered 
but did not normalize. Few non severe adverse effects (mainly, nausea) occurred and resolved 
following withdrawal from therapy. Thus, cinacalcet was proven to be effective in reducing and 
normalizing serum calcium in PHPT patients and was safe and well tolerated. However, serum 
PTH remained higher than normal range, suggesting limited beneficial effects of cinacalcet on the 
clinical manifestations of PHPT other than hypercalcemia (14). The effects of cinacalcet on 
skeletal manifestations of hyperPTH have not been evaluated in this study.  However, evidence 
from the literature suggests no significant effects of cinacalcet on bone mineral density and/or 
fracture risk. Concomitant treatment with anti-catabolic drugs should be considered in PHPT 
patients with hypercalcemia and overt bone disease (14,15). Moreover, even though cinacalcet is 
effective in controlling hypercalcemia and well tolerated by most patients, the high costs could 
limit its use in the long-term management of PHPT patients.  
In our experience, surgery has proved to be safe, with few transient complications, and effective, 
since none experienced disease persistence and/or recurrence. In our series, all patients achieved 
normal calcium and  PTH levels 24 hour after operation, and the values remained within normal 
limits during the whole duration of follow up. One patient who underwent surgery was found to 
have a parathyroid cancer at histological examination, without pathognomonic symptoms and 
signs that could have raised pre-surgical suspicious. Despite accounting for approximately 1% of 
PHPT, parathyroid cancer is often difficult to diagnose pre-operatively and should be considered 
in the differential diagnosis, when choosing the treatment strategy of PHPT  (16,17).  
In line with results from previous studies (1), our results confirm that parathyroidectomy remains 
the first line curative approach to the majority of PHPT cases, while medical treatment with 
cinacalcet represents an effective alternative aiming reducing serum calcium in selected patients 
with PHPT (18-21). In 2008 the European Medicine Agency (EMA) has approved the use of 
cinacalcet to reduce hypercalcemia in patients with PHPT in whom parathyroidectomy is not 
clinically appropriate or is contraindicated, despite indicate on the basis of serum calcium levels 
(www.ema.europa.eu). More recently, cinacalcet has also been approved by the Food and Drug 
Administration (FDA) for treatment of severe hypercalcemia in patients with PHPT who are 
unable to undergo surgery (www.fda.gov). Patients with persisting PHPT after failed surgery or 
inoperable ones due to co-morbidities should also be offered medical therapy (22).  
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Finally, cinacalcet may be used to reduce calcium levels in preparation for parathyroidectomy (22).  
The main limitation of the present study is the lack of any data concerning bone involvement in 
iperPTH patients and changes in bone density and fracture risk in the two groups of patients, the 
ones undergone surgery and those under medial therapy, during follow-up. A longer study 
evaluating also bone mineral density and fracture would be of value in assessing the long-term 
effects of cinacalcet.  
In conclusion, surgery remain the mainstay in PHPT treatment,  but cinacalcet treatment has 
gained prominence as a non-invasive treatment in selected PHTH patients, demonstrating to be 
effective in short- and long-term controls of hypercalcemia, though bone mineral density does not 
improve More study and prolonged follow-up are necessary to better define the long term effects 
of cinacalcet on mortality and morbidity in PHTH and its safety. 
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